









Markets
/
Stocks
/
nasdaq-xcur
/

Exicure Inc

XCUR

4.480USD

-0.130-2.82%

Market hours （ET）Quotes delayed by 15 min

1.06MMarket Cap

LossP/E TTM



Exicure Inc

4.480

-0.130-2.82%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Exicure Inc

Currency: USD Updated: 2026-03-27

Key Insights

Exicure Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 218 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Exicure Inc's Score

Industry at a Glance

Industry Ranking

218 / 391

Overall Ranking

459 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Exicure Inc Highlights

StrengthsRisks

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Undervalued

The company’s latest PE is -5.62, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 42.04K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Exicure Inc is 4.76, ranking 385 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

4.76

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

0.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.83

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.00

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Exicure Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Exicure Inc is 6.47, ranking 269 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.62, which is -131.67% below the recent high of 1.78 and -181.57% above the recent low of -15.83.

Score

Industry at a Glance

Previous score

6.47

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 218/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

No earnings forecast score is currently available for Exicure Inc. The Biotechnology & Medical Research industry's average is 8.07.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Exicure Inc is 7.36, ranking 55 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.15 and the support level at 3.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.88

Change

-1.52

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.102

Buy

RSI(14)

52.414

Neutral

STOCH(KDJ)(9,3,3)

36.767

Sell

ATR(14)

0.375

High Vlolatility

CCI(14)

-1.075

Neutral

Williams %R

55.361

Sell

TRIX(12,20)

0.550

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

4.499

Sell

MA10

4.525

Sell

MA20

4.230

Buy

MA50

4.385

Buy

MA100

4.756

Sell

MA200

5.323

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Exicure Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 12.77%, representing a quarter-over-quarter increase of 123.35%. The largest institutional shareholder is The Vanguard, holding a total of 42.04K shares, representing 0.66% of shares outstanding, with 118.92% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Exicure Hitron Inc. Employees

3.33M

DGP Co., Ltd.

492.61K

CBI USA, Inc.

163.66K

Abingworth Management Limited

281.64K

The Vanguard Group, Inc.

Star Investors

42.04K

+51.03%

Geode Capital Management, L.L.C.

29.32K

+54.63%

BlackRock Institutional Trust Company, N.A.

5.45K

+105.20%

Morgan Stanley Smith Barney LLC

158.00

UBS Financial Services, Inc.

18.70K

-28.80%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Exicure Inc is 1.28, ranking 324 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 4.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Exicure Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.